

# **L** Core Project R030D030604

#### O Details

Projects	Name	Award	Publications	Repositories	Analytics
1R03OD030604-01	Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing	\$297,000.00	9 publications	0 repositories	0 properties

### Publications

Published works associated with this project.

ID	Title	Authors	R C R	SJ R	Cita tion s	Cit./ yea r	Journal	Publ ishe d	Upda ted
35337371 🗗	Considerations and challenges for sexaware drug repurposing.	Jennifer L Fisher	1. 46	2. 03	9	4.5	Biology of Sex Differences	2,02 2	Oct 26,

		4 more Brittany N Lasseign e							2024 (2 weeks ago)
37533331 🗹 DOI 🗹	Evaluating cancer cell line and patient- derived xenograft recapitulation of tumor and non-disease	Avery S Williams2 more Brittany N Lasseign e	1. 05	0	3	3	Cancer Rep (Hoboken)	2,02 3	Oct 26, 2024 (2 weeks ago)
36602970 ♂ DOI ♂	Ten simple rules for using public biological data for your research.	Vishal H Oza 9 more Brittany N Lasseign e	0. 61	1. 65 2	2	2	PLoS Computational Biology	2,02 3	Oct 26, 2024 (2 weeks ago)
37824797 🗷	Computational Advancements in Cancer Combination Therapy Prediction.	Victoria L Flanary 3 more Brittany	0. 46	2. 24 9	2	2	JCO Precision Oncology	2,02	Oct 26, 2024 (2

		N Lasseign e							weeks ago)
37217845 🗹 DOI 🗗	Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and	Elizabet h J Wilk 9 more Brittany N Lasseign e	0. 39	1. 44 6	1	1	Molecular Medicine	2,02 3	Nov 8, 2024 (3 days ago)
37362157 ☑ DOI ☑	Sex-biased gene expression and gene- regulatory networks of sex-biased adverse event drug targets	Jennifer L Fisher2 more Brittany N Lasseign e	0	0	0	0	bioRxiv	2,02 3	Oct 26, 2024 (2 weeks ago)
37090499 <b>♂</b> DOI <b>♂</b>	Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-disease	Avery S Williams2 more Brittany N Lasseign e	0	0	0	0	bioRxiv	2,02 3	Oct 26, 2024 (2 weeks ago)

38167211 🗹 DOI 🗗	Sex-biased gene expression and gene- regulatory networks of sex-biased adverse event drug targets	Jennifer L Fisher 2 more Brittany N Lasseign e	0	0. 71	0	0	BMC pharmacology & toxicology	2,02 4	Oct 26, 2024 (2 weeks ago)
38531616 🗹 DOI 🗗	Signature reversion of three disease- associated gene signatures prioritizes cancer drug repurposi	Jennifer L Fisher 7 more Brittany N Lasseign e	0	0. 78 9	0	0	FEBS Open Bio	2,02 4	Oct 26, 2024 (2 weeks ago)

## Notes

RCR Relative Citation Ratio

SJR Scimago Journal Rank



#### Notes

Repository For storing, tracking changes to, and collaborating on a piece of software.

PR "Pull request", a draft change (new feature, bug fix, etc.) to a repo.

Closed/Open Resolved/unresolved.

Avg Issue/PR Average time issues/pull requests stay open for before being closed.

Only the main /default branch is considered for metrics like # of commits.

# of dependencies is totaled from all manifests in repo, direct and transitive, e.g. package.json + package-lock.json.

### Analytics

Traffic metrics of websites associated with this project.

#### Notes

Active Users <u>Distinct users who visited the website</u> 2.

New Users <u>Users who visited the website for the first time</u> **?**.

Engaged Sessions <u>Visits that had significant interaction</u> **?**.

"Top" metrics are measured by number of engaged sessions.

Generated on Nov 11, 2024

Developed with support from NIH Award U54 OD036472